Q4 2025 GeneDx Holdings Corp Earnings Call Transcript
Key Points
- GeneDx Holdings Corp (WGS) reported strong quarterly revenues of $121 million, marking a 27% year-over-year increase.
- Exome and genome revenues grew by 32% year-over-year, with an organic growth rate of 42% when excluding a one-time payer recovery.
- The company has reaffirmed its full-year 2026 guidance, projecting total revenues between $540 million to $555 million.
- GeneDx has a significant competitive advantage with its Infinity data set, the world's largest and most diverse rare disease data set.
- The company is expanding its sales force significantly, nearly tripling it to capture growth opportunities in untapped markets.
- The company faces challenges with high denial rates in new outpatient markets, which could impact reimbursement rates.
- Weather-related disruptions have affected test volumes, with potential impacts on quarterly performance.
- Despite a strong sales force, there is still a significant portion of the market that remains untapped, indicating potential barriers to adoption.
- The NICU market, while promising, has shown slower-than-expected ramp-up in ordering patterns.
- GeneDx is in a phase of heavy investment, which may impact short-term profitability as the company prioritizes market capture over immediate margin optimization.
Good day, and thank you for standing by. Welcome to the GeneDx third-quarter 2025 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Sabrina Dunbar, Investor Relations. Please go ahead.
Thank you, operator, and thank you to everyone for joining us today. On the call, we have Katherine Stueland, President and Chief Executive Officer; and Kevin Feeley, Chief Financial Officer. Earlier today, GeneDx released financial results for the fourth quarter ended December 31, 2025.
Before we begin, please take note of our cautionary statement. We may make forward-looking statements on today's call, including about our business plans, guidance and outlook. Forward-looking statements inherently involve risks and uncertainties and only reflect our view as of today, February 23, and we are under no obligation to update.
When discussing our results, we refer to non
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
